期刊文献+

人非小细胞肺癌A549细胞异质性研究 被引量:1

Heterogeneity of human non-small cell lung cancer cell line A549
下载PDF
导出
摘要 目的:分析肺癌A549细胞的异质性特征。方法:有限稀释法分离A549细胞的单个克隆细胞并扩大培养,对亲代与子代细胞进行生长、转移等特征的分析,了解A549细胞内部存在的异质性特征。结果:共获得6个A549细胞子细胞株,与亲代细胞比较,各子代细胞在细胞增殖能力和转移特征方面存在明显差异(P<0.05)。结论:A549细胞存在细胞增殖能力和转移特征的异质性,可能与肿瘤的发生转移相关。 Objective:To analyze the heterogeneity of lung cancer cell line A549.Methods: Limiting dilution was used to isolate the single clones of A549 cells and expanded for culture.Then, the growth and metastasis of the parental and offspring cells were analyzed to determine the heterogeneity of A549 cells.Results:Six sub-cell lines were isolated.There were significant differences in the proliferation and metastasis between the parental and offspring cells.Conclusion:A549 cells show heterogeneity of cell proliferation and metastasis, and the heterogeneity may be related to tumor metastasis.
作者 石兴源 艾亮梅 黄文瑾 聂豪 余宏伟 蔡隆梅 周同冲 傅文凡 Shi Xingyuan Ai Liangmei Huang Wenjin Nie Hao Yu Hongwei Cai Longmei Zhou Tongchong Fu Wenfan(Fourth Department of Radiation Oncology, Tumor Hospital Affiliated to Guangzhou Medical University, Guang- zhou, Guangdong 510095, China)
出处 《广州医科大学学报》 2016年第6期1-3,共3页 Academic Journal of Guangzhou Medical University
基金 广州市医药科技项目(20142A011023)
关键词 非小细胞肺癌 肿瘤异质性 non-small cell lung cancer tumor heterogeneity
  • 相关文献

参考文献8

二级参考文献153

  • 1史朝晖,姜希宏,赵峰,王伟.RelA反义寡核苷酸对胰腺癌细胞增殖活性的影响[J].中华实验外科杂志,2004,21(8):917-919. 被引量:3
  • 2周静,赵刚,刘涛,王春友.实体肿瘤干细胞的研究进展[J].中华实验外科杂志,2006,23(1):122-123. 被引量:24
  • 3刘国艳,瞿全新,糜若然,齐静.RNA干扰技术抑制切除修复交叉互补基因1对卵巢上皮性癌细胞顺铂敏感性的影响[J].中华妇产科杂志,2006,41(5):339-342. 被引量:20
  • 4谢峻,谈锋.植物来源抗肿瘤药物研究进展[J].中草药,2007,38(2):285-289. 被引量:30
  • 5Morimoto E,Inase N,Mlyake S,et al.Adenovirus-mediated suicide gene transfer to small cell lung carcinoma using a tumor-specific promoter.Anticancer Res,2001,21:329-331.
  • 6Miller AB,Hoogstraten B,Staquet M,et al.Reporting results of cancer treatment.Cancer,1981,47:207-214.
  • 7Sharma S,Neale MH,Di Nicolantonio F,et al.Outcome of ATPbased tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma.BMC Cancer,2003,3:19.
  • 8Jemal A, Siegel R, Ward E, et al. Cancer statistics [J]. CA Cancer J Clin, 2008, 58(2): 71-96.
  • 9Fukuoka M, Kris M, Giaccone G et al. Phase II trails of gefitinib (Iressa, ZD1839): rapid and durable objective responses in patients with advanced non- small- cell lung cancer (IDEAL1 and IDEAL2) [J]. Lung Cancer, 2003, 41 (Suppl 2): S247-S248.
  • 10Fuster L M, Sandier A B. Select clinical trials of erlotinib (OSI2 774) in non-small-cell lung cancer with emphasis on phase III out comes [J]. Clin Lung Cancer, 2004, 6(Suppl 1): S24-S29.

共引文献71

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部